Chemicals soared, but monsoon and a tax windfall mask the organic quarter
Reported profit jumped 509% to ₹693 crore, but ₹474 crore of that is a one-time tax reversal. The adjusted number—₹147 crore, up 28%—is solid; Chemicals led with 33% growth. But Bioseed collapsed 26%, SFS barely moved, and monsoon risk has risen. No FY27 guidance complicates the outlook.
₹693 Cr
+509% YoY
–₹474 Cr
one-time
–₹79 Cr
one-time
₹147 Cr
+28% YoY
The headline number is eye-catching: profit up 509%, revenue up 9.5%, PBDIT up 12%. But the real story lies in what inflated the headline. ₹474 crore of the ₹693 crore PAT is a one-time MAT credit reversal from a six-year tax reconciliation with authorities—money the company is realizing now, not earning this quarter. Strip that and the asset-sale gains, and the adjusted PAT is ₹147 crore, a solid but unspectacular +28% organic growth. That gap between reported and organic is where the quarter's substance lives.
Where the profit came from
On the call, Pratik Tholiya (Dolat Capital) asked directly: is the tax reversal one-time? The CFO's answer was clear. Of the ₹693 crore PAT, ₹474 crore is a six-year MAT credit reconciliation—an ITAT (tax appeal) favorable order recognized this quarter, not an operational win. Of that ₹474 crore, ₹376 crore is a deferred tax asset (future cash benefit); the rest hits the P&L. The company's effective tax rate will settle around 19% for the next 5–10 years (down from 35% historically, thanks to a rate cut to 25%), but this quarter's pop is a restatement, not a run-rate.
The segment picture: Chemicals surge, agri stumbles
The organic growth story hinges on one segment: Chemicals revenue jumped 33% YoY, with PBDIT up 24% to ₹274 crore, despite elevated input costs (energy, LNG) and geopolitical headwinds. Caustic soda volumes held steady (82% utilization), ECU prices firmed 7%, and new downstream projects (aluminium chloride, calcium chloride) are in final pre-commissioning for Q2 launch. The segment is the growth engine.
But the picture fractures across the portfolio. Bioseed—a historically cash-generative business—swung from +₹42 crore PBDIT last year to –₹9 crore this quarter, a 51% YoY revenue decline. The culprit: delayed monsoon rains cut kharif sowing acreage by 15–20%, and 2025-26 bumper productivity left excess seed inventory now pressuring margins. Management admits 'a large part [of demand] lost for FY27.' Shriram Farm Solutions (SFS), a proxy for agri health, grew just 2% YoY in revenue, though PBDIT margins expanded 22% on better farmer realization. Urea PBDIT fell ₹15 crore YoY (₹38 → ₹23 Cr) due to LNG cost spikes, despite government subsidy protection.
Sowing of crops has been pretty low, by almost 15% to 20% has been lower sowing, which means the demand is also a little low.
Management's claims vs. what holds up
Chemicals delivered robust 33% revenue growth
SFS profitability expanded despite muted volume growth
Strong order book in Fenesta; robust growth expected
Navigated quarter with stringent cost discipline
PAT of ₹693 Cr reflects strong operating performance
The Chemicals and SFS margin stories hold up: revenue growth and realized PBDIT gains are real. But three claims need unpacking. On Fenesta's 'robust' order book: yes, ₹1,000 crore is substantial, but order intake grew just 4% YoY—lower than expected by management. The West Asia crisis has delayed customer decision-making. On cost discipline: management faced elevated input costs (LNG, energy, freight), and while operational leverage helped Chemicals, margin compression in Bioseed, Ethanol, and Urea shows the headwinds stuck. And on the PAT claim—this is the crux—the +509% number is misleading without the asterisk.
What changed on this call
Downstream chemical integration is accelerating. Aluminium chloride and calcium chloride plants at Bharuch are in final pre-commissioning; commercial production expected Q2 FY27. This ties into a broader chlorine integration strategy: management targets 50% chlorine captive consumption now, then 85% post-projects (via pipelines to customers and regional tie-ups). This is execution—the projects are concrete and near-term.
Renewable energy capex is ramping. The company signed a 58 MW hybrid renewable deal with Serentica Renewables for Bharuch; total 176 MW target across Bharuch and Kota. Partial commissioning is underway (25 MW average injected in July). This improves energy security and long-term cost competitiveness, but the near-term margin uplift is incremental.
PVC tariff support has been reinstated by the government. After customs duty was waived and Chinese imports surged, the government reinstated the duty and set a MIP (Minimum Import Price) of ₹766/MT. This supports domestic pricing, but demand remains soft (Q2 expected soft per management). PVC volume was down 25% YoY despite price gains of 22%—the tariff defends margins, not volumes.
Demerger intent is public; timeline vague. The company confirmed a decision to proceed with a multi-SBU structure but said the government application filing is a 'FY27 objective'—exact timeline 'difficult to give now.' No strategic shift, but a capital structure move to unlock hidden value.
The bull-bear ledger
Chemicals +33% revenue, PBDIT +24%—world-class execution in a core segment
Renewable energy ramp (176 MW) will lower energy volatility and improve long-term margins
Downstream chemical integration (Al/Ca chloride Q2) is a concrete margin lever
Strong balance sheet; net debt ₹1,649 Cr, EBITDA run-rate ~₹1.5 L Cr, 1.1x leverage
Reported PAT of ₹693 Cr leans 68% on one-time items; organic +28% is solid but not spectacular
Bioseed PBDIT swung from +₹42 Cr to –₹9 Cr; monsoon risk caps FY27 agri earnings
SFS revenue +2%, Urea PBDIT –39% (one-time abated)—agri-linked segments struggling
No FY27 revenue or PAT guidance; management cites monsoon and geopolitical uncertainty
PVC volume –25% despite tariff support; demand recovery uncertain
Stock is –27% from all-time high, below all major moving averages; post-result price action faded
How the street is positioned—and what it's saying
Price action faded after the initial pop. The stock rose 0.11% on day 1 post-announcement, fell 1.53% by day 3, and was down 2.22% by day 5. This is the market's own verdict: the headline is impressive, but the street isn't convinced by the adjusted story. The pop didn't hold because, adjusted for one-times, the quarter is solid but not a beat—and without forward guidance, there's no conviction on FY27.
The technicals are bearish. The stock is trading at ₹1,026.7, down 27.13% from its all-time high of ₹1,409. It is below its 20-day average (₹1,032.87), 50-day average (₹1,035.34), and 200-day average (₹1,136.97). RSI is 49.4 (neutral, not oversold). The 52-week range is ₹945–₹1,409; the stock is 8.63% above the low but still in a bear trend. Volume is increasing on this decline—a bearish signal.
Institutional flows show no conviction either. FII ownership is flat at 3.97% (no change from prior quarters). DII has inched up 0.25 percentage points to 8.56%, but that's modest. Promoter ownership remains stable at 66.52%—no insider selling near the highs, but also no insider buying to signal confidence. The steady ownership profile suggests the street is waiting on guidance and monsoon clarity before re-engaging.
Risks, ranked by how much they should concern a holder
Monsoon deficiency; Kharif sowing remains 15–20% below normal
HighBioseed demand stays depressed; SFS volumes flat; full-year agri EBITDA could fall ₹50–80 Cr. Management already flags 'large part [of demand] lost.'
PVC import pressure persists despite tariff reinstatement; demand remains soft in Q2–Q3
HighVolume stays down 15–25%; Vinyl segment PBDIT gains (now +88%) reverse. Company runs at lower utilization despite high capacity discipline.
Geopolitical escalation (West Asia conflict) drives energy and freight costs higher; LNG spikes again
MediumUrea PBDIT falls further; Chemicals cost inflation outpaces yield/price gains; consolidated margin compression of 100–150 bps.
Bioseed inventory excess unclears; margin takes write-down hit in H2
MediumPBDIT goes from –₹9 Cr in Q1 to worse in Q2 (inventory markup loss). Swing of ₹20–30 Cr Bioseed PBDIT risk for full year.
Downstream chemical projects (Al/Ca chloride, renewable energy) miss Q2 commissioning timeline
MediumChlorine integration benefit deferred; renewable energy margin uplift pushed to later quarters. Full-year EBITDA benefit misses by ₹15–25 Cr.
Demerger filing delayed beyond FY27; capital structure unlock stalls
DimStock valuation multiple remains at conglomerate discount; no rerate event FY27. But long-term value still created post-filing.
The debate
What to watch next
1 · Q2 al/ca chloride commissioning and margin impact
If the downstream projects start commercial production on schedule in Q2, and chlorine integration ramps to 50%+ captive, Chemicals PBDIT can re-accelerate. Conversely, any delay signals execution risk and pushes margin uplift to H2. Watch the project commentary on the Q2 call for timeline confidence.
2 · Monsoon and Kharif sowing recovery (Aug–Sep 2026)
If Aug–Sep rains normalize, kharif sowing can bounce back toward trend and Bioseed demand can recover in H2. That swing could justify ₹50–70 Cr full-year Bioseed PBDIT repair (from –₹9 Cr this quarter). If rains stay patchy, Bioseed and SFS earnings stay under pressure full year, capping consolidated growth.
3 · FY27 guidance or commentary—any forward signal on revenue or margin
The absence of guidance on the Q1 call leaves the street without a yardstick. On Q2, watch for management to offer a FY27 revenue growth band or EBITDA margin outlook (even if hedged by monsoon/geopolitical caveats). Clarity on capex phasing and demerger filing timeline would also reset expectations.
DCM Shriram is executing a real strategy in Chemicals and investing for structural competitiveness (renewables, integration). But this quarter's earnings are uneven: Chemicals surged, agri collapsed, and the bottom line leans 68% on one-time tax benefits. Adjusted profit of ₹147 crore (up 28%) is solid; consolidated revenue growth of 9.5% is defensible. Yet monsoon has clobbered near-term agri earnings, and the street has repriced the stock 27% from its high, waiting on evidence that management can navigate macro headwinds and deliver the FY27 guide it has not yet given. The honest read is steady execution, not a step-change. The number to track from here is organic adjusted PBDIT—if that can sustain 15%+ YoY growth into Q2, despite monsoon overhang and import competition, then the long-term story (renewables, downstream, demerger) has traction. Until then, HOLD. Wait for monsoon clarity and Q2 capex updates before re-engaging.
DCM Shriram Q1 PAT rockets to ₹692 Cr on one-time tax credit; core growth a steady ~9%
PAT +508.13% YoY · revenue +9.54% · margins flat
₹3,784.67 Cr
+9.54% YoY
₹692.17 Cr
+508.13% YoY
18.16%
+14.9pp YoY
₹44.42
DCM Shriram reported consolidated PAT of ₹692.2 Cr for Q1 FY27, more than 5x the ₹113.8 Cr of a year ago — but the jump is almost entirely a tax-line event, not operating outperformance. A favourable Income Tax Appellate Tribunal ruling (July 3, 2026) on a Section 80-IA claim let the company reverse ₹98.05 Cr of provisions and recognise ₹376.25 Cr of deferred-tax MAT credit, flipping the tax expense to a net ~₹418 Cr credit. Layered on top were ₹79.4 Cr of exceptional gains (₹67.68 Cr Mokila land sale + ₹11.74 Cr on the Shriram Polytech/Teknor Apex stake sale). Strip these out and adjusted PAT is roughly ₹140 Cr against ₹113.8 Cr — a steady ~23% underlying rise, not +508%.
Q1 FY-2027 vs prior quarters
The operating engine grew but did not surge: revenue from operations was ₹3,784.7 Cr, up 9.5% YoY and 12.2% QoQ, while profit before exceptional items and tax rose 14.4% to ₹194.7 Cr. Operating margin held around 9.5% (vs 9.3% a year ago and 11.1% last quarter), so the reported NPM leap to ~18% is a tax artifact, not margin expansion. Chemicals & Vinyl carried the quarter — segment revenue ₹1,391.8 Cr (+25% YoY) and profit ₹242.6 Cr (+31%) — directly validating management's prior-call thesis that Chemicals, Fenesta and Farm Solutions would drive growth (Fenesta revenue also rose 22% to ₹303.1 Cr). Sugar & Ethanol stayed loss-making at −₹9.3 Cr, though the loss narrowed sharply from −₹37.4 Cr on seasonality, while Bioseed swung to a −₹10.9 Cr seasonal loss and Fertiliser profit softened to ₹19.5 Cr.
The stock went into the print at ₹1,050, up 2.2% over the past month of trading.
For context: this is the second-highest quarterly PAT of the last 6 quarters; PAT has now risen for 4 consecutive quarters.
What the summary numbers don't show
EPS (after exceptional) ₹44.42 consolidated / ₹45.62 standalone — Shriram Polytech became a JV (Teknor Apex) w.e.f. April 17, 2026
Management expects continued revenue growth driven by key segments like Chemicals, Fenesta, and Shriram Farm Solutions. While acknowledging short-term volatility in sectors like PVC due to geopolitical factors and potential trade policies, the company maintains a positive long-term outlook. Strategic initiatives includ
— This quarter: met
Against management's FY27 framing — continued segment-led growth plus ₹1,000-1,200 Cr capex including renewables and sustainability — the print is on-track: the July 17 signing for 58 MW of renewable power fits the stated capex/energy-efficiency agenda, and the Polytech-to-JV conversion (effective April 17, 2026) explains the consolidation change and part of the exceptional gain. No formal earnings guidance or street consensus is on record for this specific quarter (the trading window had only just reopened), so the result is best read on its own operating merits. The CHRO resignation (effective July 2026) and the 37th AGM set for August 18 are governance housekeeping, not earnings drivers.
W1
Chemicals & Vinyl durability — ₹242.6 Cr segment profit (+31% YoY) against management-flagged PVC/geopolitical volatility in coming quarters
W2
Sugar & Ethanol recovery from the −₹9.3 Cr Q1 seasonal loss as the cane cycle turns
W3
FY27 capex execution vs the guided ₹1,000-1,200 Cr, including the newly-signed 58 MW renewable power project
Clean digital PDF. PAT hugely inflated by two one-offs: (1) exceptional GAINS — consol ₹79.42 Cr (₹11.74 Cr stake-sale + ₹67.68 Cr Mokila land sale; standalone ₹106.03 Cr as stake gain there is ₹38.34 Cr); (2) a ~₹474 Cr one-time TAX CREDIT (reversal of ₹98.05 Cr provisions + ₹376.25 Cr deferred-tax MAT credit) after a favourable ITAT ruling on a Sec 80-IA claim, turning tax into a net credit. Consol also adds ₹1.27 Cr JV profit share → net profit ₹693.44 Cr (owners ₹692.75 Cr). Exceptional gain shown in brackets is a credit that increases PBT.
Uneven growth amid macro headwinds—Chemicals strong, agri weak
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Chemicals and Fenesta beat prior 'continued growth' expectation; SFS soft on monsoon (explained). Underlying PAT +28%, but headline obscured by one-times. No numeric targets set; next quarter will be first test.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Chemicals led with 33% growth, but Bioseed collapsed (–26%), SFS barely grew (+2%), and reported PAT of ₹693 Cr is misleading (₹474 Cr is one-time tax reversal; adjusted ₹147 Cr +28% is the reality). Monsoon risk and lack of FY27 guidance cap near-term. Long-term setup solid (renewables, capex, demerger), but execution uncertainty and macro headwinds warrant caution.
₹3784.7 Cr
Revenue · +9.5% YoY₹693.4 Cr
Reported PAT · +509.2% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
Chemicals delivered robust 33% revenue growth
MET₹33% YoY growth confirmed; PBDIT +24% to ₹274 Cr despite elevated input costs
SFS profitability expanded despite muted volume growth
METRevenue +2% YoY; PBDIT +22% to ₹30 Cr on better mix and realization
Strong order book in Fenesta; robust growth expected
OVERSTATEDOrder intake +4% (lower than expected per Amit); total order book ~₹1,000 Cr. Termed 'strong' but intake soft due to West Asia crisis.
Navigated quarter with stringent cost discipline
MISSInput costs rose (elevated energy, LNG prices). Yield/mix gains offset in some segments. Margin compression in Bioseed, Ethanol vs. prior year.
PAT of ₹693 Cr reflects strong operating performance
OVERSTATEDPAT includes ₹474 Cr one-time tax reversal + ₹79 Cr asset sales. Adjusted PAT ₹147 Cr (+28% YoY) is true operating growth; reported PAT misleading.
Earnings quality
What changed since the last call
PVC domestic demand pressure worsened
DowngradeGovernment waived customs duty temporarily; Chinese imports surged. Volume fell 25% YoY. Government now reinstated duty + MIP (₹766/MT). Near-term demand remains soft (Q2 expected soft); margin under pressure.
Bioseed cash generation reversed
DowngradeQ1 FY27 PBDIT –₹9 Cr vs +₹42 Cr Q1 FY26. Monsoon delay cut sowing 15–20%; excess seed inventory from 2025-26 high productivity now pressuring margins. Management sees 'large part lost' for FY27.
Renewable energy capex accelerating
UpgradeSigned 58 MW deal with Serentica for Bharuch. Total 176 MW planned (50% already running). Improves energy security, decarbonization, long-term cost competitiveness. Mechanism concrete, but revenue impact on FY27 margins incremental.
Downstream chemical projects ramping Q2
NeutralAl chloride, Ca chloride at Bharuch in final pre-commissioning; commercial start Q2. Chlorine integration target 50% (then 85% with customer ties). Supports margin improvement but execution dependent.
Sugar pricing firm, inventory normalization ongoing
NeutralSugar prices ~₹4,450/quintal, expected firm. Inventory fell to 20.8 lakh quintals (vs 27.7 lakh prior year). Global sugar market moving to deficit (2026-27). Supportive, but ethanol allocation policy remains uncertain and sugarcane cost volatility high.
The Q&A
Moderate pressure. Pratik (Dolat) pressed on SFS profitability drivers and ethanol strategy; management answered clearly. Sairama (investor) challenged on power costs and competitive positioning; Amit declined to disclose per-kWh (cited location/product variability). Subhankar (SKS) pushed on Fenesta order intake weakness; Amit acknowledged it was lower than expected due to West Asia crisis but defended order book strength. Management held ground, did not backtrack on numbers.
Caustic soda pricing near-term — Pratik Tholiya, Dolat Capital
PartialECU currently just below ₹30,000; expect this range or higher (cautious). Chlorine currently –₹7,000 to –₹8,000 (negative margin). Forward guidance hard; geopolitical uncertainty.
SFS profitability margin expansion despite flattish top line — Pratik Tholiya, Dolat Capital
AnsweredThree drivers: strong farmer reach, R&D new products (better value to farmer), built credibility. July monsoons good in pockets, but sowing down 15–20% overall. Difficult to project; focused on product quality and relationships.
Ethanol business profitability and grain-based pivot — Pratik Tholiya, Dolat Capital
AnsweredYes, optimizing margins dynamically. Currently maize margins good; can go up to 260 KLD grain. But no capex to grow capacity. Depends on government policy and relative margins.
Tax reversal one-time nature and cash impact — Pratik Tholiya, Dolat Capital
AnsweredSix-year reconciliation of tax filing vs. books (deferred). ITAT positive order triggered recognition. INR376 Cr is MAT credit (cash-future). Tax bracket moved 35% → 25%; with MAT, effective tax rate ~19% for 5–10 years (cash outgo, P&L still 25%).
Sugar crushing outlook and next-year harvest impact — Abhinav Mandowara, Aequitas Investments
DodgedToo early to predict given current monsoon. Will comment next quarter.
Sugar price trajectory given global deficit — Abhinav Mandowara, Aequitas Investments
PartialDifficult to say, but should be firm for next couple of months.
Urea business outlook amid high global LNG prices — Abhinav Mandowara, Aequitas Investments
AnsweredIndia urea regulated by FICC rules; government sets return. High intl prices increase govt subsidy burden, not domestic mfg margin. Govt typically pays subsidy on time. Not impacted by intl prices (pass-through); only cash-flow timing risk.
5-year company vision and focus areas — Sairama, Individual Investor
AnsweredGrow consistently. Invested in all except Urea and Cement. Focus on value-added (epichlorohydrin, epoxy, Al chloride). Buying stakes in suppliers/buyers for integration (e.g., epoxy factory Oct 2025, DNV stake in Fenesta). Bullish on India; cost-competitive manufacturing.
Power cost competitiveness and cost producer positioning — Sairama, Individual Investor
PartialWe are amongst lowest-cost producers. Continuous investment: 2019 new plant, 2024–25 120 MW coal plant (efficient, closed inefficient), now 176 MW renewable. Power cost varies by location, source, product; not prudent to disclose single number.
Chlorine integration strategy and PVC expansion — Sairama, Individual Investor
AnsweredChlorine integration crucial. After current projects (Al chloride, Ca chloride), ~50% captive consumed. Strong partnerships with customers via pipelines at Bharuch + regional tie-ups → ~85% chlorine will be tied up. No PVC capex announced.
Fenesta order intake growth and business outlook — Subhankar Ojha, SKS Capital
AnsweredYes, lower than expected due to West Asia crisis (decision delays). Total order book ~₹1,000 Cr is robust. Business growing; setting up new platforms (wooden doors). Very bullish.
Debt level increase YoY and capex plan — Subhankar Ojha, SKS Capital
AnsweredDebt increase over full year (Jun 25 to Jun 26): two acquisitions ~₹450 Cr + capex ~₹1,000 Cr. No major new capex announced beyond ongoing ₹1,000 Cr for FY27. Debt/EBITDA ~1.1x.
Net borrowing trajectory end-FY27 — Subhankar Ojha, SKS Capital
AnsweredSimilar levels, maybe ₹200 Cr reduction. ₹1,000 Cr capex ongoing. Sugar season dynamics will matter (inventory). Governed by debt/EBITDA ≤ 1.5x (not breach). AA+ rating at current levels.
Demerger timeline and process — Sandeep Baid, Individual Investor
PartialClear decision to proceed. Working on multiple SBU structure issues. Objective: file govt application in FY27. Process takes time; exact timeline difficult to give now.
Bioseed recovery in Q2 after monsoon improvement — Sandeep Baid, Individual Investor
AnsweredLarge part of demand lost. July monsoon good in pockets only; patchy, excessive some places, dry others. Sowing in our regions still 15–20% lower. Overall monsoon recovery minimal for our portfolio.
Guidance
No explicit FY27 revenue target; expects continued growth in Chemicals, Fenesta, Shriram Farm Solutions
LowPrior call aspiration, not numeric. Q1 results show Chemicals +33% (strong), Fenesta +22% (solid), SFS +2% (soft). No FY27 revenue CAGR or absolute target given.
No margin guidance. Expects PBDIT improvement from renewable energy ramp, downstream projects (Al chloride, Ca chloride) capex completion.
LowOPM 11.0% Q1 reflects input cost inflation (LNG, energy) offset by Chemicals mix. No FY27 target set. Dependent on monsoon, geopolitical, energy cost trajectory.
FY27 capex ~₹1,000 Cr (ongoing projects); no major new announcements expected
HighCommunicated clearly. Includes downstream chemical projects (Al/Ca chloride Q2), renewable energy (176 MW Bharuch+Kota), Fenesta expansion. Debt/EBITDA to stay ≤1.5x.
Risks the call surfaced
Monsoon dependency
HighBioseed and SFS highly exposed to Kharif sowing acreage. Q1 sowing down 15–20%; if monsoon deteriorates further, full-year agri EBITDA could contract significantly.
Vinyl import competition
HighPVC volumes down 25% YoY despite price +22%. China exports surged when duty waived; though duty reinstated + MIP (₹766/MT) now in place, import pressure persists. Q2 demand expected soft.
Geopolitical / commodity volatility
HighWest Asia conflict drove energy & freight volatility. LNG prices spiked (urea PBDIT fell ₹15 Cr), freight elevated, feedstock movements disrupted ECH/epoxy. Chlorine now negative ₹7–8k/MT (margin pressure on caustic integration).
Bioseed inventory excess
Medium2025-26 high productivity created excess seed inventory. Q1 sowing shortfall prevented clearance. If Kharif demand remains weak, inventory risk (obsolescence, valuation haircut) grows.
Capex execution & project delays
Medium₹1,000 Cr FY27 capex includes downstream chemical projects (Al/Ca chloride, expected Q2 startup) and renewable energy (176 MW, partial commissioning). Any delay defers margin uplift; cost overruns would compress ROCE.
Management
Score 7/10. Clear on business metrics and segment drivers. Transparent on one-time adjustments (tax reversal, asset sales). Cautious on forward guidance (cites unpredictable geopolitical, monsoon). Refuses to disclose some operational details (per-kWh power cost, citing location/product variation). Fair balance between transparency and operational discretion. Chemicals +33%, Fenesta +22% met/exceeded prior 'continued growth' guidance. SFS +2% soft (monsoon explained). Underlying PAT +28% solid. Capex on track (renewable power in Jul). ROCE stable at 13.6%. Debt/EBITDA well-managed 1.1x. No guidance misses this quarter because no numeric targets given.
1 · Q2 FY27
Aluminum chloride, calcium chloride Bharuch projects commercialization; chlorine integration +50%
2 · Q2–Q3 FY27
Monsoon outcome for Kharif; Bioseed sowing recovery (or further damage if poor rains)
3 · Jul–Sep 2026
Renewable energy ramp-up (176 MW; part commissioned Jul avg 25 MW); cost competitiveness boost
Long-term setup solid (renewables, capex, demerger), but execution uncertainty and macro headwinds warrant caution.